Navigation Links
Idenix Pharmaceuticals to Present at the Canaccord Adams Hepatitis C Conference
Date:4/4/2008

CAMBRIDGE, Mass., April 4, 2008 /PRNewswire-FirstCall/ -- Idenix Pharmaceuticals, Inc. (Nasdaq: IDIX) announced today that Idenix management will present an overview of its Hepatitis C program at the upcoming Canaccord Adams Hepatitis C Conference on Wednesday, April 9, 2008 at 1:30 p.m. ET at the St. Regis Hotel in New York, NY.

The live and archived webcast of the company presentation can be accessed under "Calendar of Events" in the Idenix Investor Center at http://www.idenix.com. Please log in approximately 5-10 minutes before each event to ensure a timely connection. The archived replays will be available on the Idenix website for two weeks following the conference.

About Idenix

Idenix Pharmaceuticals, Inc., headquartered in Cambridge, Massachusetts, is a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral and other infectious diseases. Idenix's current focus is on the treatment of infections caused by the hepatitis C virus and HIV. For further information about Idenix, please refer to http://www.idenix.com.

Idenix Pharmaceuticals' Contacts:

Media: Teri Dahlman (617) 995-9905

Investors: Amy Sullivan (617) 995-9838


'/>"/>
SOURCE Idenix Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Idenix Pharmaceuticals to Present at the Eleventh Annual Lehman Brothers Global Healthcare Conference
2. Idenix Pharmaceuticals Reports Fourth Quarter and Year-End 2007 Financial Results
3. Idenix Pharmaceuticals to Present at the SIGnificant Investment Options in Healthcare Conference
4. Idenix Pharmaceuticals to Present at the JP Morgan 26th Annual Healthcare Conference
5. Idenix Pharmaceuticals Reports Third Quarter and Nine Month Financial Results
6. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
7. Indevus Pharmaceuticals Licenses European Rights for VANTAS(R) to Orion Corporation
8. ISTA Pharmaceuticals Engages Cowen as Financial Advisor
9. Alseres Pharmaceuticals, Inc. Complies With NASDAQ Rule Regarding Recently Filed 10-K
10. Barr Pharmaceuticals, Inc. Executive Bios
11. Biotest Pharmaceuticals Corporation Responds to Orphan Drug Act Announcement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... ... 24, 2017 , ... With ProGlass Prism users now have the ability to ... control over position, rotation, distortion, edge softness, edge blur, chromatic aberration, individual glass position ... With ProGlass Prism users are given the tools and effects to generate a ...
(Date:2/24/2017)... ... February 24, 2017 , ... The Radiology Business ... in radiology marketing programs at the annual Building Better Radiology Marketing Programs ... Worth Hotel in Fort Worth, Texas. Nine awards are given out in five categories. ...
(Date:2/23/2017)... ... February 23, 2017 , ... On February ... a letter to withdraw previous guidance issued by the Obama Administration ... guidance issued in May 2016 by the Obama Administration came in response to ...
(Date:2/23/2017)... ... February 23, 2017 , ... Los Angeles-based weight loss surgeon ... TV’s “Mama June: From Not to Hot,” which will begin airing on February 24, ... known to millions from the 2012 reality television series, “Here Comes Honey Boo Boo.” ...
(Date:2/23/2017)... , ... February 23, 2017 , ... Dr. David Mahon ... Henderson, NV 89052. Dr. Mahon was named a 2017 Top Patient Rated Henderson ... is an online directory that recognizes local physicians and dentists who have earned high ...
Breaking Medicine News(10 mins):
(Date:2/23/2017)... , Feb. 23, 2017 Visiomed, ... and services since 1997, is changing the landscape ... technology providing patients with pro-active, custom-made solutions. Recognizing ... for instant and affordable healthcare without walls, Visiomed ... high-level devices developed with healthcare professionals that is ...
(Date:2/23/2017)... -- ITL Limited, ( ASX: ITD ), an innovative diversified healthcare ... ended 31 December 2016 compared with the previous corresponding period. A ... here . Highlights ... Earnings per share of 2.2 cents (Dec 2015: 1.2 ... $15.7m; up 11%) Profit before tax of $2.12m ...
(Date:2/23/2017)... -- Research and Markets has announced the addition of ... report to their offering. ... The latest research Fibromyalgia Drugs Price Analysis and Strategies ... Fibromyalgia market. The research answers the following questions: ... and their clinical attributes? How are they positioned in the Global ...
Breaking Medicine Technology: